Recent Updates — IBO
Impact BioMedical Inc. filed a Certificate of Amendment to its Certificate of Incorporation with the Secretary of State of Nevada on September 23, 2026, effecting a one-for-twelve point six two (1-for-12.62) reverse stock split of its common stock. The transaction became effective at 12:01 A.M. EST on that date and began trading on a split-adjusted basis under the existing ticker symbol IBO on the NYSE American with a new CUSIP number. The split reduced the issued and outstanding shares from approximately 107.8 million to 8.6 million, while leaving authorized share count, par value, and voting rights unchanged. Fractional shares were converted to full shares. The filing was delayed due to clerical processing errors by the Nevada Secretary of State, with the company receiving the file-stamped amendment on October 6, 2026. Impact BioMedical Inc. operates in the medical device industry.
Impact Biomedical Inc. announced that Zoar Limited filed a Form F-4 registration statement with the SEC on September 10, 2026, in connection with their previously announced business combination. The filing includes a preliminary proxy statement/prospectus for Impact shareholders to vote on the merger. Completion of the transaction is subject to SEC effectiveness of the Registration Statement, shareholder approval, and NYSE American listing approval. Upon closing, the combined entity will operate as a pharmaceutical company focused on developing and supplying active pharmaceutical ingredients and intermediates for special therapeutic treatment areas.
Impact Biomedical Inc. announced a reverse stock split at a ratio of 1-for-12.62, effective September 23, 2026, to support its proposed merger with Zoar Limited and regain NYSE American listing compliance. The transaction reduces outstanding shares from approximately 107.8 million to 8.5 million, with fractional shares rounded up. This action follows shareholder authorization in December 2025 for a split between 1-for-12.48 and 1-for-50. Impact Biomedical Inc. discovers and patents technologies for biopharmaceuticals and consumer healthcare.